Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations.
Read More…
Industry, Sector and Symbol
Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Phone650-421-8100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.59 million
Profitability
Miscellaneous
Employees132
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Codexis (NASDAQ:CDXS) Frequently Asked Questions
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
How were Codexis' earnings last quarter?
Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.04. The biotechnology company earned $12.32 million during the quarter, compared to analysts' expectations of $14.90 million. Codexis had a negative net margin of 23.13% and a negative return on equity of 21.60%. View Codexis' Earnings History.
When is Codexis' next earnings date?
What price target have analysts set for CDXS?
5 brokerages have issued 1 year price objectives for Codexis' stock. Their predictions range from $19.00 to $25.00. On average, they anticipate Codexis' share price to reach $22.30 in the next year. This suggests a possible upside of 65.9% from the stock's current price. View Analyst Price Targets for Codexis.
What is the consensus analysts' recommendation for Codexis?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.
What are Wall Street analysts saying about Codexis stock?
Here are some recent quotes from research analysts about Codexis stock:
- 1. According to Zacks Investment Research, "Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. " (8/12/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of CDXS and our 12-month price target of $16.50 per share. We derive our price target based on the average of three valuation methods: 1) price-sales multiple analysis applying a 3x multiple to our 2025 risk-adjusted revenue estimate discounted at 12%; 2) price-earnings multiple analysis applying a 23x multiple to our 2025 estimated earnings discounted at 12%; and 3) discounted free cash flow analysis assuming a 12% discount rate and a 2% terminal growth rate." (1/14/2019)
Has Codexis been receiving favorable news coverage?
Media coverage about CDXS stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Codexis earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Codexis.
Are investors shorting Codexis?
Codexis saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 5,030,000 shares, an increase of 7.7% from the August 30th total of 4,670,000 shares. Based on an average daily volume of 471,500 shares, the short-interest ratio is presently 10.7 days. Approximately 9.4% of the company's shares are short sold. View Codexis' Current Options Chain.
Who are some of Codexis' key competitors?
Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Codexis own?
Who are Codexis' key executives?
Codexis' management team includes the folowing people:
- Mr. John J. Nicols, Pres, CEO & Director (Age 55)
- Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
- Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
- Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & Marketing
- Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 73)
Who are Codexis' major shareholders?
Codexis' stock is owned by a number of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.55%), Essex Investment Management Co. LLC (0.31%), Roubaix Capital LLC (0.19%), Ingalls & Snyder LLC (0.18%), Pratt Collard Advisory Partners LLC (0.11%) and Comprehensive Portfolio Management LLC (0.06%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.
Which major investors are selling Codexis stock?
CDXS stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Strs Ohio. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch. View Insider Buying and Selling for Codexis.
Which major investors are buying Codexis stock?
CDXS stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Roubaix Capital LLC, Comprehensive Portfolio Management LLC, Essex Investment Management Co. LLC, Pratt Collard Advisory Partners LLC and Envestnet Asset Management Inc.. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.
How do I buy shares of Codexis?
Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Codexis' stock price today?
One share of CDXS stock can currently be purchased for approximately $13.44.
How big of a company is Codexis?
Codexis has a market capitalization of $784.36 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.
What is Codexis' official website?
How can I contact Codexis?
Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]
MarketBeat Community Rating for Codexis (NASDAQ CDXS)
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
